Prolactin receptor binding proteins and uses thereof
The present invention encompasses PRLR binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hPRLR and neutralize hPRLR activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hPRLR and for inhibiting hPRLR activity, e.g., in a human subject suffering from a disorder in which hPRLR activity is detrimental. Also included in the invention are anti-PRLR antibody drug conjugates (ADCs).
AbbVie Inc.
Y C C C G A C A A C G G G C A G C A C G C C A C G G
Y02A C07K C07K C07K G01S A61P C07K A61K A61K C07K G08G G08G G06K C07K A61P G06V C07K A61K C07K G08G C07K C07K A61P C07K G08G G01S
additional additional additional additional inventional inventional additional inventional inventional additional inventional inventional inventional additional inventional inventional additional additional additional inventional inventional additional inventional additional inventional inventional
Edward B. Mark David A. Qian Russell A. Archana Chung-Ming Debra Kenton L. Charles W. Jieyi Enrico L.
Reilly Anderson Egan Zhang Judge Thakur Hsieh Chao Longenecker Hutchins Wang Digiammarino